Collectively, we demonstrated that the clinical efficacy of carboplatin in ovarian cancer patients was associated with polymorphisms of CX3CL1 [rs223815 (G>C) and rs682082 (G>A)]. This evidence concerns the gene CX3CL1 and ovarian carcinoma.